Stress its going down

Waiting for Pan Borneo Highway, MRT3, ECRL. Fingers cross.

How you justify your comment?

Market sentiment is bad. This counter will fly soon.

Market on sales. BUY BUY BUY !

Hold or sell this stock?

Lets go lets go. Big project coming.

What's the news on this?

Got volume today

0.47 good mo? The chart looking good.

HSR Project coming?

They are focusing on next year.

So all these newspaper are lies?

For real?

UOB KAY HIAN. It's in a PDF don't know how to share it.

 Multi-pronged catalysts to sustain supercharged growth beyond 2021. We believe
Scomnet will emerge as one of the most prominent global healthcare proxies in Malaysia
and poised to deliver explosive earnings in FY21. This will be mainly driven by: a) resilient
earnings visibility from its strong medical orderbooks on hand; b) incremental revenue from
new medical products (D’Clot Catheter, Colonoscopy GI and Gastroscopy GI which will begin
mass production in 1Q21; customer M’s D’Clot and new clients’ blood clotting product); c)
near-term capacity expansion to fulfil explosive demand for medical segment’s products; d)
significant contribution from new automobile client – customer P from 3Q21 onwards; and e)
transfer to healthcare sector and mainboard listing which could catalyse a potential valuation
rerating.
 Maintain BUY with a target price of RM2.40. Post meeting, we have trimmed our 2020-
21 revenue forecasts by 12% and 10% respectively to reflect lower contributions from
Mermaid Medical and PSA on the slower orderbook projections. We are also assuming a
full conversion of existing warrants into our valuations, factoring in share base of 857.3m
shares and theoretical cash increment of RM140m. In terms of valuation (refer RHS
valuation table), we have pegged our target price to 35x 2021F PE, its 3-year mean and at
a discount to Bursa Malaysia Healthcare Index of 43x.
INVESTMENT HIGHLIGHTS
 Medical segment: SMP will see its full potential in FY21. SMP’s growth will be fuelled
by several new products which are poised for commercial production from 2021 onwards.
a) For customer A, the spotlight will be on its Colonoscopy GI, Gastrocopy GI and
Duodenoscopy GI which is expected to contribute about 15-20% of incremental group
revenue from 2021 onwards. The overwhelming demand for its endoscopy cables,
which has seen a tremendous sales leap of several folds compared to pre-MCO
levels, will also significantly enhance earnings.
b) For customer E, SMP will continue to benefit from the expansion of medical
orderbook with organic yoy growth of at least 10-16% for its existing products, while
there are also about seven projects with customer E on hand.
c) For customer M, the mass production of its D’Clot HD Catheter has been pushed
back due to the delays in product training processes amid COVID-19 disruptions.
That said, this is just a temporary setback and production should be able to start
immediately once the doctors are able to conduct physical training and complete the
production requirements.
d) We also understand that SMP has secured a new client with a prominent new blood
clotting product for dialysis. While Scomnet recently presented the product to FDA in
Los Angeles, the approval results should be announced in Feb/Mar 21. Notably, the
US Navy Force has signed an agreement to receive supply of this blood clotting
product. We believe this product can contribute positively to SMP’s earnings as early
as 2Q21 next year immediately after FDA approval, given that SMP has already
allocated the facilities and equipment required for commercial production.
 Automobile segment: Growth trajectory from customer P. The emergence of
Supercomal Advanced Cables’ (SAC) latest key customer P will enhance the growth of
Scomnet’s automobile segment. The agreement from this customer, which allows SAC to
supply wire harnessing and fuel tanks (higher margin), is expected to contribute about 20-
30% incremental revenue to SAC’s current revenue base in 2021, with subsequent years
to see higher revenue contributions. 2021’s earnings growth will be backed by new
revenue streams from this customer. We also understand that customer P has recently
put in another RM6.6m capex into SAC to purchase wire harness and fuel tank
production equipment.

MONEY TALK
Supercomnet Technologies (SCT MK)
Staging For A Stronger Comeback
3Q20 was an uneventful quarter dragged by forex losses, cost overrun and higher
raw material cost for a new project start-up. That said, we understand these were just
temporary setbacks which should not recur after the improvement in learning curve.
Scomnet is staging for a stronger comeback,backed by strong orderbook visibility
from its broad spectrum of key clients. Maintain BUY with target price of RM2.40.
RESULTS HIGHLIGHTS
 A temporary blip. Supercomnet Technologies (Scomnet) recorded a dismal 3Q20 core
net profit of RM5.5m (+3.5% qoq, +19.6 yoy), bringing 9M20 core net profit to Rm13.8m
which only made up 51% of our full-year estimate. Nevertheless, 3Q20 revenue grew 7.8%
yoy to RM37.8m, backed by stronger sales from both the medical and automobile
segments.
 Bottom-line shortfall and margin downtick on exceptional outflows. Despite stronger
revenue in the quarter, we noticed a plunge in net margin that impacted the bottom-line
numbers. On a yoy basis, the slight decline in net margin (-1.1% yoy) was mainly due to
labour and raw material cost overrun, driven by one of its key medical clients’ urgent
demand surge for its endoscope cable. The rejection rate of this product spiked during the
quarter, causing higher wastage of raw materials as well as overtime shifts to fulfil the
overwhelming demand. All that being said, we understand that all these are non-recurring
items as management has taken the necessary steps to achieve better efficiency with cost
normalisation expected from 4Q20 onwards.
 More clarity on SMP’s robust orderbook guidance... Our recent channel check with
management revealed that orderbook volume for Scomnet’s medical segment,
Supercomal Medical Products (SMP), remains strong, with orderbook visibility until 2Q21
and 1Q22 for key clients – customer E and customer A respectively. Note that both
customers made up about 90% of SMP’s revenue in 2019.
 …but slight disruption from COVID-19 impact. Due to the COVID-19 disruption, there
are some reduction in orders volume from its customer M. Vis-à-vis the decent sales
projection from this customer which could boost its earnings by 25% from 3Q20 onwards,
the mass production has been delayed on COVID-19 disruption. Nevertheless, the
shortfall of revenue contribution from this customer was partially offset by stronger demand
from customer A and customer E.

I am holding and worried at the same time.

Wahhh dropping further

I think I still have faith on this counter. Future wise they are healthy. I think this latest QR is due to the FOREX thingy.

Any take on this?

Not much movement after QR. Guess is time to hold till next QR.

Hold it is. Cannot let you buy cheap ! hahaha

I think i have decided to hold it and hope to enjoy the long run.

Yeah wei. Can explain the quarter report a little? It states there is unaudited

I am hoping for that to happen Jazzkhor. Hoping.

Yeah wei. You think the QR will be out by today?

Not sure. I heard is something to do with Forex. Not sure what it is either.

What does institutional price means?

Think today got some issue. Maybe something to do with forex since their clients are all overseas.

I agree with Makeabuck. It is like discounted rate now. Fundamentals are good. Their clients Ambu and Edward Life is doing so well. So i dun see it will tumble this counter.

I am definitely holding till their QR release. I think the local market is worried about this Thursday only. Gomen wants state of emergency. So i guess local players all scared and let go now. Thats my 2cents.

I got a feeling is some people don’t want to wait for QR to be release in case it is bad and letting go now.

QR should be good. Is it normal for ppl to sell before QR?

https://simplywall.st/stocks/my/capital-goods/klse-scomnet/supercomnet-technologies-berhad-shares/news/how-does-supercomnet-technologies-berhads-klsescomnet-ceo-pa

The quarter report is gonna be awesome! Wait for it..........

Really hoping that they will hit the Main Market.

Has scomnet switch to Main Market yet?

https://simplywall.st/stocks/my/capital-goods/klse-scomnet/supercomnet-technologies-berhad-shares/news/can-supercomnet-technologies-berhad-klsescomnet-continue-to-grow-its-returns-on-capital/

Dividend is later today right? So to hold or to sell?

Can't wait for the day that Scomnet enters to the Main Market.

U guys think that scomnet will be put to Main Market?

Buy volume is high

Strong this company. Is definitely a company to invest not to trade.

Lai Liao

Something is brewing. Wait for it.

RM10?

I am surprise that no one talks about the new investor. 5.4% into the company stake is insane.

I believe in Scomnet. Super strong company. Worth the investment.

Bro DannyArcher where you read insider disposing, sell? Is it from the 4th September news?